Tag: Viking Therapeutics

Investors are reassessing Viking Therapeutics' clinical trial data as concerns emerge about patient discontinuation rates in the study of oral ...

The obesity treatment market is becoming increasingly competitive as multiple pharmaceutical companies advance their GLP-1 receptor agonist candidates. Viking Therapeutics ...

Viking Therapeutics finds itself navigating significant market headwinds in the wake of recent clinical data presentations. The company's stock experienced ...

Shares of Viking Therapeutics experienced a dramatic sell-off after the biopharmaceutical company released Phase 2 trial results for its oral ...

Viking Therapeutics shares encountered selling pressure as the market digested Phase II trial data for its oral obesity treatment candidate ...

Viking Therapeutics finds itself at a pivotal juncture, navigating a complex landscape with a portfolio of promising metabolic disease treatments. ...

A notable institutional investor has established a new position in Viking Therapeutics, providing fresh momentum for the biopharmaceutical stock. This ...

Shares of Viking Therapeutics are experiencing significant volatility as investors weigh impressive efficacy data against emerging safety concerns for its ...

Viking Therapeutics Inc. has experienced extreme stock volatility after announcing results from a key clinical study for its obesity treatment ...

Viking Therapeutics experienced a severe market selloff following the release of clinical data for its obesity treatment candidate VK2735. While ...